News
Benlysta is the first and only approved autoinjector biologic for both systemic lupus erythematosus and lupus nephritis ...
The Michael Jon Barlin Pediatric Lupus Research program provides funding for research projects that have the potential to ...
The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...
The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy.
The FDA has approved a 200 mg/mL autoinjector of belimumab (Benlysta) for at-home subcutaneous use in children aged 5 years ...
Benlysta is supplied as a single-dose prefilled autoinjector or prefilled syringe containing 200mg/mL of belimumab for SC use. The prefilled syringe has not been studied in pediatric patients aged ...
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...
The American College of Rheumatology has updated its systemic lupus erythematosus treatment guidelines for the first time ...
High and low doses with increased IMT, moderate (0.15–0.4 mg/kg/day) doses with decreased IMT in children [26] and adults [27] IMT: Intima-media thickness; SLE: Systemic lupus erythematosus ...
10d
GlobalData on MSNUS FDA approves GSK’s Benlysta autoinjector for lupus nephritisThe US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five ...
GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results